|
1
|
George J, Maas L, Abedpour N, Cartolano M,
Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, et
al: Evolutionary trajectories of small cell lung cancer under
therapy. Nature. 627:880–889. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roviello G, Zanotti L, Cappelletti MR,
Gobbi A, Senti C, Bottini A and Generali D: No advantage in
survival with targeted therapies as maintenance in patients with
limited and extensive-stage small cell lung cancer: A
literature-based meta-analysis of randomized trials. Clin Lung
Cancer. 17:334–340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu SV, Reck M, Mansfield AS, Mok T,
Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J,
Califano R, Nishio M, et al: Updated overall survival and PD-L1
subgroup analysis of patients with extensive-stage small-cell lung
cancer treated with atezolizumab, carboplatin, and etoposide
(IMpower133). J Clin Oncol. 39:619–630. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldman JW, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab, with or without tremelimumab, plus
platinum–etoposide vs. platinum-etoposide alone in first-line
treatment of extensive-stage small-cell lung cancer (CASPIAN):
Updated results from a randomised, controlled, open-label, phase 3
trial. Lancet Oncol. 22:51–65. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide vs. platinum–etoposide in
first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen
G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T,
Pan Y, et al: Effect of first-line serplulimab vs. placebo added to
chemotherapy on survival in patients with extensive-stage small
cell lung cancer: The ASTRUM-005 randomized clinical trial. JAMA.
328:1223–1232. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim D, Kim HJ, Wu HG, Lee JH, Kim S, Kim
TM, Kim JS and Kim BH: Intrathoracic progression is still the most
dominant failure pattern after first-line chemo-immunotherapy in
extensive-stage small-cell lung cancer: Implications for thoracic
radiotherapy. Cancer Res Treat. 56:430–441. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeremic B, Shibamoto Y, Nikolic N, Milicic
B, Milisavljevic S, Dagovic A, Aleksandrovic J and
Radosavljevic-Asic G: Role of radiation therapy in the
combined-modality treatment of patients with extensive disease
small-cell lung cancer: A randomized study. J Clin Oncol.
17:2092–2099. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gore EM, Hu C, Sun AY, Grimm DF,
Ramalingam SS, Dunlap NE, Higgins KA, Werner-Wasik M, Allen AM,
Iyengar P, et al: Randomized phase II study comparing prophylactic
cranial irradiation alone to prophylactic cranial irradiation and
consolidative extracranial irradiation for extensive-disease small
cell lung cancer (ED SCLC): NRG oncology RTOG 0937. J Thorac Oncol.
12:1561–15670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slotman BJ, van Tinteren H, Praag JO,
Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C and
Senan S: Use of thoracic radiotherapy for extensive stage
small-cell lung cancer: A phase 3 randomised controlled trial.
Lancet. 385:36–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lo CK, Mertz D and Loeb M:
Newcastle-Ottawa Scale: Comparing reviewers' to authors'
assessments. BMC Med Res Methodol. 14:452014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slim K, Nini E, Forestier D, Kwiatkowski
F, Panis Y and Chipponi J: Methodological index for non-randomized
studies (minors): Development and validation of a new instrument.
ANZ J Surg. 73:712–716. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cumpston M and Flemyng E. Chapter IV:
Updating a review [last updated August 2023]. Higgins JPT, Thomas
J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA: Cochrane
handbook for systematic reviews of interventions. Version 6.5
(updated August 2024). Cochrane; 2024, www.training.cochrane.org/handbookJune
24–2024PubMed/NCBI
|
|
15
|
Wu JJ, Huang JW, Hsu KH, Huang YH, Chen
KC, Tseng JS, Yang TY and Chang GC: Thoracic radiotherapy may
improve the outcome of extensive stage small cell lung carcinoma
patients treated with first-line immunotherapy plus chemotherapy.
Anticancer Drugs. 33:e842–e849. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel RL, Miller KD and Wagle NS: Cancer
statistics, 2023. CA: A Cancer J Clin. 73:17–48. 2023.PubMed/NCBI
|
|
17
|
Farago AF and Keane FK: Current standards
for clinical management of small cell lung cancer. Transl Lung
Cancer Res. 7:69–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oronsky B, Reid TR, Oronsky A and Carter
CA: What's new in SCLC? A review. Neoplasia. 19:842–847. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barrows ED, Blackburn MJ and Liu SV:
Evolving role of immunotherapy in small cell lung cancer. Semin
Cancer Biol. 86:868–874. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Zhao Y, Ma T, Shao H, Wang T, Jin S
and Liu Z: Radiotherapy for extensive-stage small-cell lung cancer
in the immunotherapy era. Front Immunol. 14:11324822023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Sheikh K, Nakajima E, Lin CT, Lee
J, Hu C, Hales RK, Forde PM, Naidoo J and Voong KR: Radiation
versus immune checkpoint inhibitor associated pneumonitis: Distinct
radiologic morphologies. Oncologist. 26:e1822–e1832. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diamond BH, Verma N, Shukla UC, Park HS
and Koffer PP: Consolidative thoracic radiation therapy after
first-line chemotherapy and immunotherapy in extensive-stage small
cell lung cancer: A multi-institutional case series. Adv Radiat
Oncol. 7:1008832022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fang M, Wang L, Gu Q, Wu H, Du X and Lai
X: Efficacy and safety of thoracic radiotherapy for extensive stage
small cell lung cancer after immunotherapy in real world. Clin Exp
Metastasis. 40:423–429. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Jing W, Jing X, Sun Y, Tang X, Guo
J, Zhang Y and Zhu H: Role of consolidative thoracic radiation in
extensive-stage small-cell lung cancer with first-line
chemo-immunotherapy: A retrospective study from a single cancer
center. Discov Oncol. 14:552023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lindblad KE and Lujambio A: Liver
metastases inhibit immunotherapy efficacy. Nat Med. 27:25–27. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
O'leary K: Liver metastases cultivate an
immune desert. Nat Rev Cancer. 21:1432021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan L, Lin Y, Fu Y and Wang J: Small cell
lung cancer with liver metastases: From underlying mechanisms to
treatment strategies. Cancer Metastasis Rev. 44:52024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Slotman B, Faivre-Finn C, Kramer G, Rankin
E, Snee M, Hatton M, Postmus P, Collette L, Musat E and Senan S;
EORTC Radiation Oncology Group and Lung Cancer Group, :
Prophylactic cranial irradiation in extensive small-cell lung
cancer. N Engl J Med. 357:664–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perez BA, Kim S, Wang M, Karimi AM, Powell
C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, et al:
Prospective single-arm phase 1 and 2 study: ipilimumab and
nivolumab with thoracic radiation therapy after platinum
chemotherapy in extensive-stage small cell lung cancer. Int J
Radiat Oncol Biol Phys. 109:425–435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Longo V, Della Corte CM, Russo A, Spinnato
F, Ambrosio F, Ronga R, Marchese A, Del Giudice T, Sergi C,
Casaluce F, et al: Consolidative thoracic radiation therapy for
extensive-stage small cell lung cancer in the era of first-line
chemo-immunotherapy: Preclinical data and a retrospective study in
Southern Italy. Front Immunol. 14:12894342024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao Y, Li B, Song R, Yang L, Zou B and
Wang L: Efficacy and safety of thoracic radiotherapy in
extensive-stage small-cell lung cancer patients receiving
first-line immunotherapy plus chemotherapy: A propensity score
matched multicentre retrospective analysis. Radiat Oncol.
19:252024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Yang D, Min Y, Liao A, Zhao J, Jiang
L, Dong X, Deng W, Yu H, Yu R, Zhao J and Shi A: First-line
atezolizumab/durvalumab plus platinum–etoposide combined with
radiotherapy in extensive-stage small-cell lung cancer. BMC Cancer.
23:3182023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hoffmann E, De-Colle C, Potkrajcic V,
Baumann D, Spengler W, Gani C and Utz D: Is consolidative thoracic
radiotherapy of extensive-stage small cell lung cancer still
beneficial in the era of immunotherapy? A retrospective analysis.
Strahlenther Onkol. 199:668–675. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Welsh JW, Heymach JV, Chen D, Verma V,
Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, et al:
Phase I trial of pembrolizumab and radiation therapy after
induction chemotherapy for extensive-stage small cell lung cancer.
J Thorac Oncol. 15:266–273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie Z, Liu J, Wu M, Wang X, Lu Y, Han C,
Cong L, Li J and Meng X: Real-world efficacy and safety of thoracic
radiotherapy after first-line chemo-immunotherapy in
extensive-stage small-cell lung cancer. J Clin Med. 12:38282023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peng J, Zhang L, Wang L, Feng H, Yao D,
Meng R, Liu X, Li X, Liu N, Tan B, et al: Real-world outcomes of
PD-L1 inhibitors combined with thoracic radiotherapy in the
first-line treatment of extensive stage small cell lung cancer.
Radiat Oncol. 18:1112023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu W, Han Z, Wang J, Zhang T, Chen D,
Feng Q, Xiao Z, Lyu J, Wang X, Deng L, et al: Safety of thoracic
radiotherapy followed by PD-1/PD-L1 inhibitors after induction
therapy in extensive-stage small cell lung cancer. Chin J Radiat
Oncol. 31:236–241. 2022.
|
|
38
|
Chen D, Zou B, Meng X, Huang W, Shao Q,
Tang X, Guo J, Hu X, Zhang Y, Fu L, et al: Safety and efficacy of
SHR-1316 combined with chemotherapy and sequential chest
radiotherapy as first-line therapy for extensive-stage small cell
lung cancer (ES-SCLC): The results from a phase II single-arm
trial. J Clin Oncol. 40 (Suppl):85632022. View Article : Google Scholar
|
|
39
|
Gross AJ, Kharouta MZ, Podder TK, Choi S
and Biswas T: Role of thoracic radiotherapy in extensive stage
small cell lung cancer (ES-SCLC) in the immunotherapy era: A
national hospital-based registry analysis. Int J Radiat Oncol Biol
Phys. 111:e4662021. View Article : Google Scholar
|
|
40
|
Daher S, Allen A, Rottenberg Y, Nasrallah
H, Yosef L, Blumenfeld PA, Wollner M, Appel S, Nechushtan H,
Moskovitz M, Bar J and Zer A: 144P Real-world data of consolidative
radiotherapy for extensive stage (ES)-SCLC treated by
chemo-immunotherapy (chemo-IO). Ann Oncol. 33:S99–S100. 2022.
View Article : Google Scholar
|
|
41
|
Cai Z, Gu X, Xie J, Cheng D, Chen J, Cheng
J, Ye J and Lv T: Safety and efficacy of thoracic radiotherapy
combined with chemo-immunotherapy in patients with extensive-stage
small cell lung cancer: A multicenter retrospective analysis.
Transl Lung Cancer Res. 12:1987–2000. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Meng F W.: Clinical study of first-line
chemotherapy and immunotherapy combined with thoracic radiotherapy
for extensive-stage small cell lung cancer. Chin J Radiat Oncol.
33:110–115. 2024.
|
